Here are six highlights:
1. TranS1 is a medical device company that designs, develops and markets products to treat degenerative spinal conditions.
2. Mr. Groppa will oversee the development and implementation of all marketing activities in his new role.
3. He will also oversee TranS1’s insurance reimbursement strategy.
4. Prior to joining TranS1, he did product development work with Blue Cross Blue Shield Association and brand marketing for IBM.
5. He earned his master of business administration from the University of Notre Dame (Ind.)
6. “Chris brings a fresh perspective to TranS1. His extensive marketing experience and work in the insurance industry is a huge asset to our company. We look forward to supporting him as he does great things at TranS1,” said Jeff Schell, TranS1’s president and CEO.
More articles on devices:
All MACs to cover Osiris Therapeutics’ Grafix for wound care: 3 points
Bone Therapeutics, Kasios extend collaboration for spinal fusion product: 3 takeaways
Global outsourced orthopedic manufacturing market to reach $2B+ by 2020: 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
